VX-478 non-peptide HIV protease inhibitor data

Partner Burroughs Wellcome presented preclinical data showing an acceptable safety profile and synergism with AZT and ddI.

VRTX (Cambridge, Mass.) said the agent

Read the full 236 word article

How to gain access

Continue reading with a
two-week free trial.